- Home
- CDIO vs EVAX Comparison
CDIO vs EVAX Comparison
Compare CDIO & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDIO
- EVAX
- Stock Information
- Founded
- CDIO 2017
- EVAX 2008
- Country
- CDIO United States
- EVAX Denmark
- Employees
- CDIO N/A
- EVAX N/A
- Industry
- CDIO Biotechnology: Commercial Physical & Biological Resarch
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CDIO Health Care
- EVAX Health Care
- Exchange
- CDIO Nasdaq
- EVAX Nasdaq
- Market Cap
- CDIO 20.2M
- EVAX 16.3M
- IPO Year
- CDIO N/A
- EVAX 2021
- Fundamental
- Price
- CDIO $0.50
- EVAX $2.53
- Analyst Decision
- CDIO Buy
- EVAX Strong Buy
- Analyst Count
- CDIO 1
- EVAX 3
- Target Price
- CDIO $2.00
- EVAX $33.33
- AVG Volume (30 Days)
- CDIO 2.5M
- EVAX 6.8M
- Earning Date
- CDIO 03-31-2025
- EVAX 03-26-2025
- Dividend Yield
- CDIO N/A
- EVAX N/A
- EPS Growth
- CDIO N/A
- EVAX N/A
- EPS
- CDIO N/A
- EVAX N/A
- Revenue
- CDIO $35,688.00
- EVAX $3,295,000.00
- Revenue This Year
- CDIO $228.74
- EVAX $9,039.73
- Revenue Next Year
- CDIO $854.55
- EVAX $1.47
- P/E Ratio
- CDIO N/A
- EVAX N/A
- Revenue Growth
- CDIO 180.90
- EVAX N/A
- 52 Week Low
- CDIO $0.19
- EVAX $2.22
- 52 Week High
- CDIO $1.86
- EVAX $22.05
- Technical
- Relative Strength Index (RSI)
- CDIO 45.05
- EVAX 40.91
- Support Level
- CDIO $0.47
- EVAX $2.43
- Resistance Level
- CDIO $0.69
- EVAX $2.80
- Average True Range (ATR)
- CDIO 0.08
- EVAX 0.31
- MACD
- CDIO 0.01
- EVAX 0.07
- Stochastic Oscillator
- CDIO 33.88
- EVAX 16.94
About CDIO Cardio Diagnostics Holdings Inc. Common stock
Cardio Diagnostics Holdings Inc is a biotechnology company that makes cardiovascular disease prevention and early detection more accessible, personalized, and precise. The company was formed to further develop and commercialize a proprietary artificial intelligence-driven integrated Genetic-Epigenetic EngineTM for cardiovascular disease to become the leading medical technology company for enabling improved prevention, early detection, and assistance in the treatment of cardiovascular disease.
About EVAX Evaxion Biotech
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.